Old and new antirheumatic drugs for the treatment of COVID-19

Joint Bone Spine. 2020 May;87(3):195-197. doi: 10.1016/j.jbspin.2020.03.013.

Authors

Maurizio Benucci¹, Arianna Damiani², Maria Infantino³, Mariangela Manfredi³, Luca Quartuccio⁴

Affiliations

¹ Rheumatology Unit Hospital, S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy. Electronic address: maurizio.benucci@uslcentro.toscana.it.
² Rheumatology Unit Hospital, S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy.
³ Immunology and Allergology Laboratory Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy.
⁴ Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, Udine, Italy.

No abstract available

Keywords: B-DMARDs; Covid-19; DMARDs; Ts-DMARDs.

Publication types

Editorial

MeSH terms

Angiotensin-Converting Enzyme 2
Antirheumatic Agents / therapeutic use*
Betacoronavirus / immunology
Betacoronavirus / pathogenicity*
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy*
Coronavirus Infections / immunology
Cytokines* / metabolism
Humans
Pandemics
Peptidyl-Dipeptidase A
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / immunology
SARS-CoV-2

Substances

Antirheumatic Agents
Cytokines
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2

Associated data

ClinicalTrials.gov/NCT04320277